Abattis Announces it has Received Deficiency List for its Controlled Substance License Applicationadmin
Vancouver, BC – February 20, 2014 – Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), Health Canada Office of Controlled Substance has issued the deficiency list for Abattis’ subsidiary, Northern Vine Canada Inc. application to obtain a Controlled Substance License for handling, analytics and extraction of Marihuana.
Abattis submitted its application to Health Canada on December 23, 2013.
The application has been reviewed and assessed by the Office of Controlled Substances of Health Canada. "We are pleased to report there were only 3 deficiencies in the application and we will address each and every item to ensure we can analyze samples and provide Certificate of Analysis for Licensed Producers ensuring the product being sold to its patients meets all standards as established in the AHP Monograph on Cannabis that Abattis supported in 2013. Our goal is to ensure that there are safe, efficacious medical marijuana products that work in the market, while researching and filing intellectual property on the compositions that we develop." stated Mike Withrow, President and CEO of Abattis.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal and adult marijuana markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical growing systems, extraction equipment/technology, and strategic marketing support to licensed growers and dispensaries. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. For more information, visit the Company’s website at www.abattis.com.
ON BEHALF OF THE BOARD
President & CEO
For further information, contact the Company’s CEO, Michael Withrow at 778-896-6536
or at email@example.com.
NEITHER THE CNSX EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.
Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s Management’s Discussion and Analysis which can be found under the Company’s profile on www.sedar.com.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME.
Posted: February 20th, 2014 under ACCESSWIRE.